Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com

Emergent BioSolutions (NYSE:EBS) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

Several other research analysts also recently commented on the stock. Benchmark lifted their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday.

Emergent BioSolutions Stock Up 1.2 %

Shares of EBS traded up $0.13 during trading hours on Friday, hitting $11.61. 1,241,520 shares of the company were exchanged, compared to its average volume of 1,077,335. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The company has a market cap of $629.19 million, a PE ratio of -2.83 and a beta of 1.60. The firm’s 50 day moving average is $9.39 and its 200-day moving average is $9.31. Emergent BioSolutions has a 52 week low of $1.42 and a 52 week high of $15.10.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.37 EPS for the quarter, beating the consensus estimate of $0.49 by $0.88. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The company had revenue of $293.80 million for the quarter, compared to the consensus estimate of $328.72 million. During the same quarter last year, the company posted ($1.44) earnings per share. On average, equities research analysts forecast that Emergent BioSolutions will post -0.63 EPS for the current fiscal year.

Institutional Trading of Emergent BioSolutions

Hedge funds have recently modified their holdings of the company. Jacobs Levy Equity Management Inc. bought a new stake in Emergent BioSolutions in the third quarter valued at about $1,547,000. Oak Hill Advisors LP acquired a new stake in Emergent BioSolutions during the third quarter valued at approximately $9,296,000. Assenagon Asset Management S.A. grew its stake in shares of Emergent BioSolutions by 74.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock valued at $6,192,000 after purchasing an additional 316,700 shares during the period. Barclays PLC raised its holdings in shares of Emergent BioSolutions by 361.6% in the 3rd quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 30,792 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Emergent BioSolutions by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company’s stock worth $4,861,000 after buying an additional 25,776 shares during the period. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.